

AD \_\_\_\_\_

AWARD NUMBER DAMD17-97-1-7259

TITLE: c-erbB-2 Receptor Signalling and Breast Cancer Metastasis

PRINCIPAL INVESTIGATOR: Ming Tan

CONTRACTING ORGANIZATION: University of Texas  
M.D. Anderson Cancer Center  
Houston, Texas 77030

REPORT DATE: August 1998

TYPE OF REPORT: Annual

PREPARED FOR: Commander  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)

2. REPORT DATE  
August 1998

3. REPORT TYPE AND DATES COVERED  
Annual (1 Aug 97 - 31 Jul 98)

4. TITLE AND SUBTITLE

c-erbB-2 Receptor Signalling and Breast Cancer Metastasis

5. FUNDING NUMBERS

DAMD17-97-1-7259

6. AUTHOR(S)

Ming Tan

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

University of Texas M.D. Anderson Cancer Center  
Houston, Texas 77030

8. PERFORMING ORGANIZATION  
REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING  
AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

19990614 058

12a. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 words)

Overexpression of the c-erbB2 gene has been shown to be correlated with poor prognosis and the number of lymph node metastases in breast cancer patients. Our recent work has demonstrated that c-erbB2 indeed enhanced the intrinsic metastatic potential of human breast cancer MDA-MB-435 cells. We hypothesize that the erbB2-encoded receptor tyrosine kinase (RTK) may enhance metastatic potential through the RTK-signaling molecules. The purpose of this study is to test whether the increased c-erbB2 tyrosine kinase activity and tyrosine autophosphorylation on the carboxyl-terminal tail may be required for the downstream signaling involved in breast cancer metastasis. We have basically completed the Task 1, 2, and 3 of the Objective 1 as stated in the Statement of Work of our proposal. We have transfected the wild-type and mutant erbB2 genes into MDA-MB-435 cells and established a panel of wild-type and mutant erbB2 gene transfectants, which can be used as the experimental system to further our studies to understand the mechanism of erbB2 gene enhanced human breast cancer metastasis. Currently, we are comparing the metastatic potential of wild-type with erbB2 mutant transfectants that express mutated erbB2 proteins in vitro and in vivo (Task 4 and 5).

14. SUBJECT TERMS

Breast Cancer, erbB2/HER-2, Metastasis, signal transduction

15. NUMBER OF PAGES  
8

16. PRICE CODE

17. SECURITY CLASSIFICATION  
OF REPORT

Unclassified

18. SECURITY CLASSIFICATION  
OF THIS PAGE

Unclassified

19. SECURITY CLASSIFICATION  
OF ABSTRACT

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

✓ Where copyrighted material is quoted, permission has been obtained to use such material.

✓ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

✓ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

✓ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

✓ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

✓ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

✓ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

✓ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
\_\_\_\_\_  
PI - Signature

\_\_\_\_\_  
Date

## **Table of Contents**

- 1. Progress Report for 1997-1998**
- 2. Appendices**

## Progress Report for 1997-1998

### A. Introduction

Breast cancer is one of the most common malignancies among women in the United States, and metastasis from this cancer is the major cause of death for these patients. Therefore, it is extremely important to uncover the basis of breast cancer metastasis. Overexpression of the c-erbB2 (also known as HER-2, *neu*) gene has been shown to be correlated with poor prognosis and the number of lymph node metastases in breast cancer patients. Our recent work has demonstrated that stable transfection of the human c-erbB2 gene into the low c-erbB2-expressing MDA-MB-435 human breast cancer cells (named 435.eB transfectants) indeed enhanced the intrinsic metastatic potential of these cells [Tan, 1997]. Because overexpression of the c-erbB2 gene has been found in ~ 30% of breast tumors, it is very important to examine the molecular mechanisms underlying the enhanced metastatic potential induced by c-erbB2 overexpression and then to design new strategies to treat this type of breast cancer metastasis. We hypothesize that the c-erbB2-encoded receptor tyrosine kinase (RTK) may enhance metastatic potential through the RTK-signaling molecules. The purpose of this proposed study is to test whether the increased c-erbB2 tyrosine kinase activity and tyrosine autophosphorylation on the carboxyl-terminal tail may be required for the downstream signaling involved in breast cancer metastasis. To address this question we will study: (1) The requirement of the tyrosine kinase domain and tyrosine autophosphorylation sites in the c-erbB2 receptor for mediating signals leading to metastasis. (2) The immediate downstream signals of c-erbB2 that may contribute to increased metastatic potential.

### B. Specific Aims

The specific Aims 1 and 2 have not been modified.

### C. Study Results and Significance

Aim 1. The requirement of the tyrosine kinase domain and tyrosine autophosphorylation sites in the c-erbB2 receptor for mediating signals leading to metastasis.

We basically completed the Task 1, 2, and 3 of the Objective 1 as stated in the Statement of Work of our proposal. To determine whether the tyrosine kinase activity and other structural motifs in the cytoplasmic domain of erbB2 receptor are required for enhancing metastatic potential, we have subcloned and transfected the kinase-deficient dominant-interfering mutant (K753M),

autophosphorylation-site mutant (Y1248F), and c-terminal-deletion mutant (C1025) and constitutively activated mutant (V659E) of the c-erbB2 receptor into human breast cancer MDA-MB-435 cells. We have established a panel of erbB2 gene transfected stable transfectants by using G418 selection. To identify those transfectants that actually produced the mutated erbB2 proteins, we performed immunoblot analysis by using antibodies against the extracellular domain of erbB2 protein. Immunoblot analysis results show that these mutant erbB2 gene transfected cell lines expressed very high mutated erbB2 proteins at different expression levels ( Appendices Fig. 1). To determine the structural changes in erbB2 mutants will result in specific changes in tyrosine-phosphorylated proteins that correlate with their effects on metastatic potential in MDA-MB-435 breast cancer cells, the tyrosine phosphorylation pattern of erbB2 proteins have been examined *in vivo*. As described in Appendices Fig. 2, western blotting using anti-phosphotyrosine antibodies was performed on protein lysates from MDA-MB-435 transfectants that express wild-type or mutant erbB2 proteins. As we expected, very low level of tyrosine phosphorylation of erbB2 protein has been found in transfectants that expressing the kinase-defective K753M mutant. This result indicate that K753M mutant protein is kinase defective in MDA-MB-435 cells. We also detected a reduction in tyrosine phosphorylation of erbB2 proteins in MDA-MB-435 transfectants expressing either the Y1248F, C1025 mutant proteins compared to those expressing the wild-type erbB2 protein, which indicate lower intrinsic tyrosine kinase activities of Y1248F, C1025. Furthermore, we detected a higher tyrosine phosphorylation of erbB2 proteins in MDA-MB-435 transfectants expressing the constitutive activated V659E mutant proteins compared to those expressing the wild-type erbB2 protein, which indicate higher intrinsic tyrosine kinase activities of this mutant.

Currently, we are comparing wild-type with erbB2 mutant transfectants that express mutated erbB2 proteins for their metastatic potentials *in vitro* and *in vivo* (Task 4 and 5).

## D. Plans

**Aim 1. To evaluate the requirement of the tyrosine kinase domain and tyrosine autophosphorylation sites in the c-erbB2 receptor for mediating signals leading to metastasis.**

Aim 1.1, Part 2 and Aim 1.2 Compare wild-type with mutant erbB2 transfectants for their metastatic potential and to evaluate whether deficiencies of tyrosine kinase activity in the c-erbB2 mutants that may affect metastatic potential in MDA-MB-435 transfectants.

Please refer to the original proposal for the detail.

**Aim 2. To investigate the immediate downstream signals of c-erbB2 that may contribute to increased metastatic potential.**

Please refer to the original proposal for the detail.

### **E. Conclusions**

We have established a panel of wild-type and mutant erbB2 gene transfectants, which can be used as the experimental system to further our studies to understand the mechanism of erbB2 gene enhanced human breast cancer metastasis.

### **F. Reference**

1. Tan M., Yao J., and Yu D. C-erbB-2 overexpression enhanced intrinsic metastatic potential in human breast cancer cells. *Cancer Res.* 57: 1199-1205, 1997.

**G. Human Subjects:** No change.

**H. Vertebrate Animals:** No change.

**I. Publications:** No paper has been published so far.

**J. Inventions and Patents:** None.

Appendices

Fig. 1 Western Blotting Shows Wild-type and Mutant erbB2 Proteins Expression




Fig.2 Western Blotting shows ErbB2 mutant Transfectants erbB2 ProteinTyrosine Phosphorylation levels

